WCG buys VeraSci in second acquisition in weeks
WCG has acquired eClinical software firm VeraSci, expanding its capabilities to support clinical trials focused on central nervous system (CNS) disorders.
The deal sees clinical research support firm WCG add VeraSci for an undisclosed amount. The numerous software and tech platforms WCG will add to its offering are aimed at improving data quality in clinical trials, including endpoint and assessment services, rater training and certification, language and translation support, and eCOA and ePRO technologies.
“VeraSci joins WCG’s CNS Group of Companies which support clinical trials focused on interventions for Central Nervous System (CNS) disorders,” WCG’s CEO VeraSci Donald Deieso told Clinical Insider.
“The WCG CNS Group includes leading scientific and technology solutions with unparalleled expertise in neurodegenerative and psychiatric diseases. VeraSci joins Medavante, Prophase, and Analgesic Solutions in the Group.”
Following the deal, VeraSci will be known as WCG VeraSci. The organization will retain its leadership structure and continue to operate from its headquarters in North Carolina.
“There are countless scientific and technology synergies that will add considerable value to our clients, who are working to address challenging conditions such as Parkinson’s, Alzheimer’s, depression, and schizophrenia,” said Deieso.
The news comes weeks after WCG acquired medical imaging firm Intrinsic Imaging for an undisclosed amount, adding services designed to support data integrity and reduce risk in clinical research.
And according to Deieso, more acquisitions in the clinical trial services space are likely. “WCG is continuously exploring additions to our growing suite of specialized solutions.”
Image: iStock/Zhanna Hapanovich